hitha

hitha

Share this post

hitha
hitha
#5SmartReads - June 9, 2021

#5SmartReads - June 9, 2021

On the risks of Aduhelm's approval, the future of democracy, and who we still follow

Hitha Palepu's avatar
Hitha Palepu
Jun 09, 2021
∙ Paid
1

Share this post

hitha
hitha
#5SmartReads - June 9, 2021
Share

Experts question FDA standards with Aduhelm approval (Axios)

Here’s the recap - the FDA approved an Alzheimer’s drug developed by Biogen and Eisai. It’s the first Alzheimer’s drug to be approved in a while - most noticeably, the first after the FDA issued guidance to ease the standards for drugs treating Alzheimer’s.

The decision to approve Aduhelm, which doesn’t show any significant benefit over the placebo, gives me a lot of pause. Approval before the confirmatory trial’s protocol and study timeline concern me. And while the FDA has no control over pricing, that the drug is extremely expensive is another cause of concern.

The FDA’s standards of safety and effectiveness of the drugs they approve has always been extremely high. I worry this is setting a bad precedent, at a time when public trust in the FDA is polarized.

Keep reading with a 7-day free trial

Subscribe to hitha to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 Hitha Palepu
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share